MAZE
Maze Therapeutics, Inc.·Healthcare
26.05
1.139%(−0.30)
Close PriceLast Updated: — ET
52W L: $9.7352W H: $53.65
Maze Therapeutics, Inc.·Healthcare
SOUTH SAN FRANCISCO, Calif. , May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph. D. , chief executive officer of Maze Therapeutics, will participate in two upcoming investor conferences: 2026 Jefferies Global Healthcare Conference in New York; presentation on Wednesday, June 3, 2026, at 3:45 p.
SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will participate in two upcoming investor conferences:
Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.
Maze Therapeutics, Inc. (MAZE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $1.15 per share a year ago.
Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late 2026 or early 2027 Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD on track to initiate in 2026 Strong balance sheet with $528 million in cash, cash equivalents and marketable securities; inclusive of net proceeds from the $150 million registered offering and $20 million MZE001 milestone payment in April 2026; cash runway expected to extend into 2029 SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for the first quarter ended March 31, 2026, highlighting recent progress and business updates.
This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just reported a notable insider sale.